These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 1675171

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia.
    Heilig M, Sjögren M, Blennow K, Ekman R, Wallin A.
    Biol Psychiatry; 1995 Aug 15; 38(4):210-6. PubMed ID: 8547442
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Shunt related changes in somatostatin, neuropeptide Y, and corticotropin releasing factor concentrations in patients with normal pressure hydrocephalus.
    Poca MA, Mataró M, Sahuquillo J, Catalán R, Ibañez J, Galard R.
    J Neurol Neurosurg Psychiatry; 2001 Mar 15; 70(3):298-304. PubMed ID: 11181849
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Somatostatin cerebrospinal fluid levels in dementia.
    Molins A, Catalán R, Sahuquillo J, Castellanos JM, Codina A, Galard R.
    J Neurol; 1991 Jun 15; 238(3):168-70. PubMed ID: 1678420
    [Abstract] [Full Text] [Related]

  • 8. Tau protein is a potential biological marker for normal pressure hydrocephalus.
    Kudo T, Mima T, Hashimoto R, Nakao K, Morihara T, Tanimukai H, Tsujio I, Koike Y, Tagami S, Mori H, Nakamura Y, Tanaka T, Mori K, Takeda M.
    Psychiatry Clin Neurosci; 2000 Apr 15; 54(2):199-202. PubMed ID: 10803815
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Biochemical investigation of normal pressure hydrocephalus in the assessment of shunt effectiveness].
    Kanki T.
    No To Shinkei; 1988 Feb 15; 40(2):163-70. PubMed ID: 3370169
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration.
    Edvinsson L, Minthon L, Ekman R, Gustafson L.
    Dementia; 1993 Feb 15; 4(3-4):167-71. PubMed ID: 8401787
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ventricular and lumbar cerebrospinal fluid concentrations of Alzheimer's disease biomarkers in patients with normal pressure hydrocephalus and posttraumatic hydrocephalus.
    Brandner S, Thaler C, Lelental N, Buchfelder M, Kleindienst A, Maler JM, Kornhuber J, Lewczuk P.
    J Alzheimers Dis; 2014 Feb 15; 41(4):1057-62. PubMed ID: 24748118
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Do concentrations of neurotransmitters measured in lumbar cerebrospinal fluid reflect the concentrations at brain level?
    Gjerris A, Gjerris F, Sørensen PS, Sørensen EB, Christensen NJ, Fahrenkrug J, Rehfeld JF.
    Acta Neurochir (Wien); 1988 Feb 15; 91(1-2):55-9. PubMed ID: 2899378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.